Zentalis Pharmaceuticals, Inc. $ZNTL Shares Sold by Goldman Sachs Group Inc.

Goldman Sachs Group Inc. decreased its stake in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) by 50.3% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 456,393 shares of the company’s stock after selling 461,714 shares during the period. Goldman Sachs Group Inc. owned about 0.63% of Zentalis Pharmaceuticals worth $726,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of ZNTL. Cerity Partners LLC raised its stake in Zentalis Pharmaceuticals by 58.7% during the first quarter. Cerity Partners LLC now owns 20,501 shares of the company’s stock valued at $33,000 after buying an additional 7,579 shares in the last quarter. State of Wyoming increased its holdings in shares of Zentalis Pharmaceuticals by 30.1% in the 1st quarter. State of Wyoming now owns 45,176 shares of the company’s stock valued at $72,000 after acquiring an additional 10,460 shares during the last quarter. Northern Trust Corp raised its position in shares of Zentalis Pharmaceuticals by 2.2% during the 4th quarter. Northern Trust Corp now owns 484,738 shares of the company’s stock valued at $1,469,000 after acquiring an additional 10,513 shares in the last quarter. Deutsche Bank AG raised its position in shares of Zentalis Pharmaceuticals by 34.1% during the 4th quarter. Deutsche Bank AG now owns 42,804 shares of the company’s stock valued at $130,000 after acquiring an additional 10,873 shares in the last quarter. Finally, Vident Advisory LLC bought a new position in Zentalis Pharmaceuticals during the fourth quarter worth $45,000.

Analyst Upgrades and Downgrades

Several analysts have weighed in on ZNTL shares. HC Wainwright upgraded shares of Zentalis Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, August 7th. Wall Street Zen raised shares of Zentalis Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Saturday, August 9th. Finally, Wells Fargo & Company lowered their price objective on shares of Zentalis Pharmaceuticals from $6.00 to $5.00 and set an “equal weight” rating for the company in a research report on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $5.84.

Zentalis Pharmaceuticals Stock Performance

ZNTL opened at $1.50 on Wednesday. The company has a market capitalization of $108.21 million, a PE ratio of -0.66 and a beta of 1.76. The stock’s fifty day moving average is $1.54 and its 200-day moving average is $1.45. Zentalis Pharmaceuticals, Inc. has a one year low of $1.01 and a one year high of $4.44.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last released its earnings results on Wednesday, August 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.19. On average, equities research analysts forecast that Zentalis Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.